Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tizanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 12/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 10/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 10/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.97 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.97 |
| ▸ | HRH2 | P25021 | 2/20 | 0.97 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.59 |
| ▸ | BLM | P54132 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tizanidine SCHEMBL6472652 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469048 | 0.99 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL20769844 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL60334 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL23498010 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471445 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL4725711 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28207600 | 0.92 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469648 | 0.91 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28345161 | 0.91 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3669 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070972-A1 | MODULATORS | XOMA US LLC (US) | 2026-03-12 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-20250288560-A1 | TIZANIDINE LIQUID PREPARATION AND USE THEREOF | FIDELITY BIOPHARMA CO. | 2025-09-18 | — | — | US | claimed |
| CN-115400123-B | Tizanidine liquid preparation and application thereof | 四川科瑞德制药股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-12263158-B2 | Tizanidine liquid preparation and use thereof | FIDELITY BIOPHARMA CO. (US) | 2025-04-01 | — | — | US | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-119264127-A | Tizanidine intermediate impurity, preparation method and intermediate detection method | 湖南方盛制药股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119157858-A | Tizanidine hydrochloride capsule and its preparation method | 杭州泓友医药科技有限公司 | 2024-12-20 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20040122065-A1 | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or buccally | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043431-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR BUCCAL AND SUBLINGUAL DELIVERY OF TIZANIDINE AND METHODS OF ADMINISTERING TIZANIDINE SUBLINGUALLY OR BUCALLY | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-05-27 | — | — | WO | claimed |
| US-20040013643-A1 | Methods for treatment of multiple sclerosis with statins | NOVLMMUNE S.A. | 2004-01-22 | — | — | US | claimed |
| WO-2003061703-A9 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS WITH STATINS | NOVIMMUNE SA (CH) | 2003-12-24 | — | — | WO | claimed |
| US-20030176472-A1 | Method of tizanidine therapy | ELAN PHARMACEUTICS, INC. | 2003-09-18 | — | — | US | claimed |
| WO-2003061703-A1 | METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS WITH STATINS | NOVIMMUNE, S.A. (CH) | 2003-07-31 | — | — | WO | claimed |
| CN-1368878-A | Drug therapy of restless leg syndrome | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-11 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |